📊 VOR Key Takeaways
Is Vor Biopharma Inc. (VOR) a Good Investment?
Pre-revenue biotech company with critically deteriorating financial fundamentals including negative shareholders' equity of -$150.4M, indicating technical insolvency on a balance sheet basis. Operating losses of $219.6M and negative operating cash flow of $38.2M create an unsustainable burn rate of approximately 4-5 quarters of cash runway at current levels, making the company heavily dependent on dilutive capital raises for survival.
Vor Biopharma Inc. Key Strengths (VOR)
- Cash position of $169.9M provides near-term liquidity for operations
- Exceptional current ratio of 31.15x demonstrates ability to meet immediate short-term obligations
- Total assets of $506.7M provide some asset base for potential restructuring or acquisition scenarios
VOR Stock Risks: Vor Biopharma Inc. Investment Risks
- Negative stockholders' equity of -$150.4M represents balance sheet insolvency; liabilities exceed assets by $150.4M
- Operating cash burn of -$38.2M per period with limited runway and no revenue generation creates imminent refinancing necessity
- Accumulated net losses of $219.6M in latest period combined with zero revenue demonstrates inability to achieve profitability or market validation
- Future capital requirements will necessitate significant equity dilution given negative net worth position
- Negative operating margins and deteriorating EPS (-5.11, down -107.2% YoY) indicate worsening operational efficiency
Key Metrics to Watch
- Cash runway in quarters remaining at current burn rate and any changes to operating cash flow
- Funding announcements and dilution impact from future capital raises
- Quarterly operating losses and trajectory toward profitability or path to revenue generation
Vor Biopharma Inc. (VOR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 31.15x current ratio provides a solid financial cushion.
VOR Profit Margin, ROE & Profitability Analysis
VOR vs Healthcare Sector: How Vor Biopharma Inc. Compares
How Vor Biopharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vor Biopharma Inc. Stock Overvalued? VOR Valuation Analysis 2026
Based on fundamental analysis, Vor Biopharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vor Biopharma Inc. Balance Sheet: VOR Debt, Cash & Liquidity
VOR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vor Biopharma Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-34.03 indicates the company is currently unprofitable.
VOR Revenue Growth, EPS Growth & YoY Performance
Vor Biopharma Inc. Dividends, Buybacks & Capital Allocation
VOR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vor Biopharma Inc. (CIK: 0001817229)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VOR
What is the AI rating for VOR?
Vor Biopharma Inc. (VOR) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VOR's key strengths?
Claude: Cash position of $169.9M provides near-term liquidity for operations. Exceptional current ratio of 31.15x demonstrates ability to meet immediate short-term obligations.
What are the risks of investing in VOR?
Claude: Negative stockholders' equity of -$150.4M represents balance sheet insolvency; liabilities exceed assets by $150.4M. Operating cash burn of -$38.2M per period with limited runway and no revenue generation creates imminent refinancing necessity.
What is VOR's revenue and growth?
Vor Biopharma Inc. reported revenue of N/A.
Does VOR pay dividends?
Vor Biopharma Inc. does not currently pay dividends.
Where can I find VOR SEC filings?
Official SEC filings for Vor Biopharma Inc. (CIK: 0001817229) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VOR's EPS?
Vor Biopharma Inc. has a diluted EPS of $-5.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VOR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vor Biopharma Inc. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VOR stock overvalued or undervalued?
Valuation metrics for VOR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VOR's AI grade for 2026?
Our dual AI analysis gives Vor Biopharma Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VOR's free cash flow?
Vor Biopharma Inc.'s operating cash flow is $-38.2M, with capital expenditures of $48.0K.
How does VOR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 31.15 (avg: 2).